| Autor: |
Hong Kan, Christopher F Bell, Julie Priest, Marni Stott-Miller, Justyna Amelio, Xue Song, Brendan Limone, Virginia Noxon |
| Jazyk: |
angličtina |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Lupus Science and Medicine, Vol 7, Iss 1 (2020) |
| Druh dokumentu: |
article |
| ISSN: |
2053-8790 |
| DOI: |
10.1136/lupus-2019-000357 |
| Popis: |
ObjectiveTo examine the effects of belimumab initiation on healthcare resource utilisation (HCRU) and costs in SLE.MethodsThis retrospective observational cohort study used healthcare administrative claims data from the IBM MarketScan Commercial Claims and Encounters Database to identify patients with SLE billing codes who received ≥1 intravenous belimumab infusion between March 2011 and December 2015. The first belimumab administration was the ‘index date’. During the 6-month postindex period, nine belimumab infusions were recommended: three during the initiation period and six during the maintenance period. HCRU and cost data for inpatient admissions, emergency department visits, physician office visits, hospital-based outpatient visits, laboratory services, other outpatient services and outpatient pharmacy prescriptions were compared in the 6-month pre/postindex periods.ResultsOf the 1879 patients with SLE included, 43% received ≥3 intravenous initiation administrations. An average of 5.3 (SD: 2.4) of the nine recommended belimumab administrations were received within 6 months. In the 6-month preindex versus postindex periods, significant reductions were noted for inpatient hospitalisations (18% vs 9%, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
